Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

168.57 -0.74 (-0.44%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

57 58 Next >

FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says ↗

August 07, 2023

Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.

Via Benzinga

PayPal Unveils USD-Backed Stablecoin, Trucking Firm Yellow Corp Files For Bankruptcy, FDA Approves First Oral Treatment For Postpartum Depression: Today's Top Stories ↗

August 07, 2023

Benzinga

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)

August 07, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Biogen Unusual Options Activity For August 02 ↗

August 02, 2023

Via Benzinga

Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years ↗

July 31, 2023

Via Benzinga

Health Care Company Biogen Announces Acquisition of Reata Pharmaceuticals ↗

July 28, 2023

Via Benzinga

Why Sage Lost Half Its Value After The FDA Approved Its Depression Drug ↗

August 07, 2023

The company gained approval for the first oral treatment for postpartum depression.

Via Investor's Business Daily

FDA Approves Sage Therapeutics/Biogen's Zuranolone For One Type Of Depression, Rejects For Another ↗

August 07, 2023

The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with

Via Benzinga

FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder

August 04, 2023

From Sage Therapeutics, Inc.

Via Business Wire

FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder

August 04, 2023

From Biogen Inc.

Via GlobeNewswire

I Was Concerned About Biogen Until I Heard These 11 Words From Its CEO ↗

July 27, 2023

Biogen shares have stagnated in recent years, but the company has a plan to change that.

Via The Motley Fool

3 ‘Strong Buy’ Biotech Stocks You Should Be Loading Up On Now ↗

August 02, 2023

Biotech stocks can be a lucrative investment opportunity, these three biotech stocks to buy now are among analyst favorites.

Via InvestorPlace

Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points ↗

August 01, 2023

Investors looking to give their portfolio a boost should consider one of these leading biotech names, which are undervalued right now.

Via InvestorPlace

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA), Talaris Therapeutics, Inc. (Nasdaq - TALS), Inpixon® (Nasdaq - INPX)

August 01, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know. ↗

August 01, 2023

Biogen also recently announced a plan to cut costs and focus investment on high-growth areas.

Via The Motley Fool

Rising Stars, Falling Trends: July's Industry ETF Winners And Losers ↗

July 31, 2023

Via Benzinga

Better Alzheimer's Drug Stock: Eli Lilly vs. Biogen ↗

July 31, 2023

By 2024, their medicines will likely be competing on the market, and one might win.

Via The Motley Fool

Could This Stock Be the Next Biotech Buyout? ↗

July 31, 2023

A buyout deal recently pushed Reata Pharmaceuticals stock 53% higher in a single trading session, leading investors to wonder who's next.

Via The Motley Fool

3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes ↗

July 30, 2023

Here are three millionaire maker drug stocks from companies whose drugs could make truly staggering profits.

Via InvestorPlace

Biotech Battlefields: 3 Stocks to Watch Amid Wall Street Turmoil ↗

July 29, 2023

There is opportunity in a crisis. Key biotech stocks amid turmoil could be the greatest deals on the market today.

Via InvestorPlace

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Reata Pharmaceuticals, Inc. (Nasdaq – RETA), Talaris Therapeutics, Inc. (Nasdaq – TALS), Inpixon® (Nasdaq – INPX), Amedisys, Inc. (Nasdaq – AMED)

July 28, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Stock Market Rallies Amid Huge Earnings, Fed Rate Hike, Inflation Data: Weekly Review ↗

July 28, 2023

Despite Thursday's downside reversal, the major indexes had a solid advance.

Via Investor's Business Daily

Biogen (NASDAQ: BIIB) Acquires Reata (NASDAQ: RETA) to Boost its Neurological Therapeutics Portfolio, Including SKYCLARYS®

July 28, 2023

Reata's Acquisition to Propel Biogen's Growth Strategy Biogen Inc. (NASDAQ: BIIB) and Reata Pharmaceuticals, Inc. (NASDAQ: RETA) have announced a

Via Spotlight Growth

Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated ↗

July 28, 2023

Earlier today, Biogen Inc (NASDAQ: BIIB) agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of

Via Benzinga

Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today? ↗

July 28, 2023

Reata Pharmaceuticals (RETA) stock is soaring higher on Friday as investors react to an acquisition deal with Biogen (BIIB).

Via InvestorPlace

Biogen Announces $7.3 Billion Acquisition Of Reata Pharmaceuticals ↗

July 28, 2023

Reata stock surged more than 50% on the news.

Via Investor's Business Daily

Biogen Bolsters Rare Disease Portfolio, Agrees To Buy Reata Pharmaceuticals With Enterprise Value Of $7.3B ↗

July 28, 2023

Biogen Inc (NASDAQ: BIIB) has agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of

Via Benzinga

Biogen to Acquire Reata Pharmaceuticals

July 28, 2023

From Biogen Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023 ↗

July 27, 2023

Via Benzinga

Neuroinflammation A Key Indicator For Alzheimer’s, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?

July 27, 2023

--News Direct--

Via News Direct

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

57 58 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.